Abstract: High-refractive-index materials have become increasingly critical for advanced photonic applications. Wurtzitestructured gallium phosphide (WZ-GaP) is particularly promising due to its ...

Chris Ogden is affiliated with the Foreign Policy Centre, London, as a Senior Research Fellow. At a major summit in Russia last year, a banknote was unveiled that carried more symbolism than monetary ...

Cells may generate their own electrical signals through microscopic membrane motions. Researchers show that active molecular processes can create voltage spikes similar to those used by neurons. These ...

Optical metasurfaces, with their ultra-thin and lightweight properties, are driving the miniaturization and planarization of optical systems. However, their development from unit-cell design to system ...

CSL Seqirus, the vaccine unit of Australian biotech CSL, has signed a pact to provide Saudi Arabia with cell-based influenza shots and help establish its production in-country. The move forms part of ...

Galapagos (NASDAQ:GLPG) ADRs dropped ~13% in the premarket on Tuesday after the Belgian biotech announced plans to wind down its cell therapy business, impacting roughly 365 employees in Europe, the U ...

Galapagos is planning to wind down its cell therapy business, completing a whiplash change that saw the biotech go from focusing on the modality to ditching it in six months. Belgium-based Galapagos ...

The immune system has a tough job: When a tiny virus invades one of our cells, that cell must detect it and, within minutes, decide what to do. If the cell quickly self-destructs, that will prevent ...

(Reuters) -Novo Nordisk has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday. Bloomberg News first reported on ...

Oct 10 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday.

Ozempic maker Novo Nordisk (NVO) is closing its cell therapy division as part of a major restructuring drive initiated under the company’s new CEO, Mike Doustdar, Bloomberg News reported on Thursday, ...

Novo Nordisk is ending all work in cell therapy, including a Type 1 diabetes program, amid CEO Maziar Mike Doustdar's reorganization. As part of the move, the company is laying off nearly all of the ...